drugset / Trial / NCT03757936
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
Timeline
- Start
- 2018-11-27
- Primary completion
- 2019-09-27
- Completion
- 2020-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Serplulimab | Monoclonal antibody | 10 mg/kg | Intravenous |